For patients suffering from acute renal failure, for the intermittent procedures, intermittent hemodialysis is currently the standard of care in both the ICU and non-ICU settings such as the acute dialysis unit.1 This method while efficient, has been associated with hemodynamic instability.1 Over the last 25 years, there have been significant technological advances in the delivery of renal replacement therapy particularly as it pertains to the critically ill population.2 In general most chronic hemodialysis patients in the acute and ICU settings are treated three times per week.

NxStage products are used for IHD treatments in both the ICU and non-ICU settings and offer a wide range of benefits to this treatment procedure. NxStage’s Medisystems division manufactures and distributes a variety of innovative disposables, providing safe, convenient, efficient, and cost effective use in hemodialysis, and extracorporeal therapies.

The Streamline® suite of products, which include Streamline, Streamline Long, and Streamline Express, may help reduce the risk of clotting with the elimination of blood-air interface. This elimination of blood-air interface may also lower heparin needs compared to conventional bloodlines and decrease the number of blood-side machine alarms.

References:
  1. Mehta RL. Supportive Therapies: intermittent hemodialysis, continuous renal replacement therapies, and peritoneal dialysis. Acute Renal Failure Chapter 19. Atlas of Diseases of the Kidney. Vol. 1. 1999.
  2. Pannu N, Gibney RTN. Renal replacement therapy in the intensive care unit. Therapeutics and Clinical Risk Management. 2005;1(2):141-150.